The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations
- PMID: 30776089
- DOI: 10.1002/jcph.1392
The Effectiveness of a Vancomycin Dosing Guideline in the Neonatal Intensive Care Unit for Achieving Goal Therapeutic Trough Concentrations
Abstract
Concern for bacterial resistance and treatment failure with vancomycin trough concentrations < 10 μg/mL have led guidelines to increase goal concentrations. There is a paucity of data evaluating vancomycin dosage necessary to achieve goals in the neonatal intensive care unit (NICU). We aimed to evaluate the implementation of a new vancomycin dosing guideline in improving trough target attainment. This retrospective study evaluated neonates in the NICU treated with vancomycin between January 2009 and December 2015. Therapeutic trough concentration attainment (10-20 μg/mL) was compared between neonates receiving vancomycin per old versus new dosing guidelines. Vancomycin trough concentrations, modeled pharmacodynamic target attainment, and nephrotoxicity were compared between groups. A total of 212 vancomycin trough concentrations (n = 91 old and n = 121 new guideline) were evaluated in 182 unique neonates. The mean ± standard deviation trough concentration achieved was 18.0 ± 7.3 μg/mL vs 8.9 ± 4.8 μg/mL in the new and old guidelines, respectively (P < .01). The new guideline resulted in a higher percentage of neonates achieving trough concentrations of 10 to 20 μg/mL (62% vs 29%; P < .01) and decreased the percentage of neonates with subtherapeutic trough concentrations (9% vs 69%; P < .01). Pharmacokinetic modeling identified postmenstrual age, days of life, and urine output as predictors of vancomycin clearance and resultant trough and area under the curve values (P < .01 for all). Trough concentrations >10 μg/mL ensured area under the curve /minimum inhibitory concentration >400 in >90% of neonates when bacteria minimum inhibitory concentration was ≤ 1 μg/mL. Nephrotoxicity was similar between groups (8.3% vs 7.7%; P = .99). In conclusion, a vancomycin nomogram designed to achieve trough concentration of 10 to 20 μg/mL improves pharmacodynamic target attainment in neonates in the NICU.
Keywords: dosing guideline; neonatal; therapeutic drug monitoring; vancomycin.
© 2019, The American College of Clinical Pharmacology.
Similar articles
-
Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.Pediatr Infect Dis J. 2015 Jul;34(7):742-7. doi: 10.1097/INF.0000000000000664. Pediatr Infect Dis J. 2015. PMID: 25629890
-
Association between vancomycin trough concentration and area under the concentration-time curve in neonates.Antimicrob Agents Chemother. 2014 Nov;58(11):6454-61. doi: 10.1128/AAC.03620-14. Epub 2014 Aug 18. Antimicrob Agents Chemother. 2014. PMID: 25136027 Free PMC article.
-
Individualized Pharmacokinetic Dosing of Vancomycin Reduces Time to Therapeutic Trough Concentrations in Critically Ill Patients.J Clin Pharmacol. 2018 Sep;58(9):1123-1130. doi: 10.1002/jcph.1273. Epub 2018 Jun 29. J Clin Pharmacol. 2018. PMID: 29957824
-
Vancomycin: pharmacokinetics and administration regimens in neonates.Clin Pharmacokinet. 2004;43(7):417-40. doi: 10.2165/00003088-200443070-00001. Clin Pharmacokinet. 2004. PMID: 15139793 Review.
-
The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.J Clin Pharm Ther. 2015 Jun;40(3):259-65. doi: 10.1111/jcpt.12270. Epub 2015 Apr 11. J Clin Pharm Ther. 2015. PMID: 25865426 Review.
Cited by
-
Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.Int J Clin Pharm. 2021 Oct;43(5):1394-1403. doi: 10.1007/s11096-021-01266-7. Epub 2021 Apr 28. Int J Clin Pharm. 2021. PMID: 33913087
-
Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.Clin Pharmacokinet. 2021 Aug;60(8):985-1001. doi: 10.1007/s40262-021-01027-9. Epub 2021 May 18. Clin Pharmacokinet. 2021. PMID: 34002357
-
Association between Vancomycin Pharmacokinetic Parameters and Clinical and Microbiological Efficacy in a Cohort of Neonatal Patients.Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0110922. doi: 10.1128/aac.01109-22. Epub 2022 Oct 12. Antimicrob Agents Chemother. 2022. PMID: 36222533 Free PMC article.
-
Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review.Antibiotics (Basel). 2021 Mar 25;10(4):347. doi: 10.3390/antibiotics10040347. Antibiotics (Basel). 2021. PMID: 33805874 Free PMC article. Review.
-
Vancomycin Prescribing Practices and Therapeutic Drug Monitoring for Critically Ill Neonatal and Pediatric Patients: A Survey of Physicians and Pharmacists in Hong Kong.Front Pediatr. 2020 Nov 30;8:538298. doi: 10.3389/fped.2020.538298. eCollection 2020. Front Pediatr. 2020. PMID: 33330263 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical